Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International Multicentric Retrospective Study on the Use of Enfortumab Vedotin + Pembrolizumab as First-line Therapy in Patients With Locally Advanced/Metastatic Urothelial Cancer (ARON-2PLUS)

NCT07420855 is registered in ClinicalTrials.gov with Aron Research Foundation Ets as lead sponsor.

NCT NCT07420855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07420855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International Multicentric Retrospective Study on the Use of Enfortumab Vedotin + Pembrolizumab as First-line Therapy in Patients With Locally Advanced/Metastatic Urothelial Cancer (ARON-2PLUS)
Lead sponsor
Aron Research Foundation Ets
Phase
Observational
Overall status
Not yet recruiting
Start date
February 28, 2026
Completion date
December 31, 2030
Enrollment
361 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic urothelial cancer, urothelial cancer